| Literature DB >> 21471522 |
Cécile Desjobert1, Marie-Hélène Renalier, Julie Bergalet, Emilie Dejean, Nicole Joseph, Anna Kruczynski, Jean Soulier, Estelle Espinos, Fabienne Meggetto, Jérome Cavaillé, Georges Delsol, Laurence Lamant.
Abstract
Although deregulated expression of specific microRNAs (miRNAs) has been described in solid cancers and leukemias, little evidence of miRNA deregulation has been reported in ALK-positive (ALK(+)) anaplastic large cell lymphomas (ALCL). These tumors overexpress the major antiapoptotic protein myeloid cell leukemia 1 (MCL-1), a situation that could compensate for the lack of BCL-2. We report that ALK(+) ALCL cell lines and biopsy specimens (n = 20) express a low level of miR-29a and that this down-modulation requires an active NPM-ALK kinase. Murine models (transgenic mice and mouse embryonic fibroblast [MEF] cells), which allow conditional NPM-ALK fusion protein expression, showed an increase of miR-29a expression in the absence of NPM-ALK. Concordant results were observed after the abolition of NPM-ALK kinase activity (siALK or PF-2341066) in NPM-ALK(+) ALCL cell lines. In addition, we showed that low expression of miR-29a, probably through methylation repression, plays an important regulatory role in MCL-1 overexpression that could promote tumor cell survival by inhibiting apoptosis. Enforced miR-29a expression was found to modulate apoptosis through inhibition of MCL-1 expression in ALCL cell lines and in a xenografted model, with a concomitant tumor growth reduction. Thus, synthetic miR-29a represents a potential new tool to affect tumorigenesis in these lymphomas.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21471522 DOI: 10.1182/blood-2010-09-301994
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113